Michael Novogratz’s Fortress Investment Trims Stake in Cardiome Pharma (CRME)

A recent 13G filing shows that Michael Novogratz’s Fortress Investment Group trimmed its passive stake in Cardiome Pharma Corp.

Keep Reading →